Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Description

The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.

Conditions

Autosomal Dominant Polycystic Kidney, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.

Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Condition
Autosomal Dominant Polycystic Kidney
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-65 years of age
  • * ADPKD diagnosis based on the modified Pei-Ravine criteria
  • * Body-mass index of ≥27 kg/m\^2
  • * Estimated glomerular filtration rate ≥ 30 mL/min/1.73m\^2
  • * Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months
  • * Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study
  • * Ability to provide informed consent
  • * Diabetes mellitus
  • * Tolvaptan usage or plans to initiate tolvaptan
  • * History of hospitalization or major surgery within the last 3 months
  • * Uncontrolled hypertension (systolic blood pressure \> 160 or diastolic blood pressure \>100 mm Hg)
  • * Pregnancy, lactation, or unwillingness to use adequate birth control
  • * Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism
  • * History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder
  • * Weight change of \>5% in the past 3 months for any reason except post-partum weight loss
  • * Inability to cooperate with or clinical contraindication for MRI including: severe claustrophobia, implants, devices, or non-removable body piercings
  • * Presence or personal history of malignant neoplasm within 5 years prior to the day of screening
  • * Personal or family history of medullary thyroid carcinoma, thyroid nodule, or multiple endocrine neoplasia type 2
  • * Prior history of pancreatitis
  • * Weight ≥450 lb

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Study Record Dates

2029-06-30